Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis

Overview of attention for article published in OncoTargets and therapy, May 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 70 Mendeley

Summary Policy documents X Dimensions citations

So far, Dimensions has found 44 publications that cite this research output.

44

The most recent citing publications are shown below. View all 44 publications that cite this research output on Dimensions.

Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence

Article in Thoracic Cancer (September 2023)

Lazertinib versus Gefitinib as First-line Treatment for <i>EGFR</i>-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

Article in Cancer Research and Treatment (June 2023)

Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan

Article in JAMA Network Open (May 2023)